BIIB
Aims: This is a 72 week multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of BIIB023 in subjects with newly diagnosed lupus nephritis.
Diagnosis: Lupus Nephritis
Principal Investigator: Neenoo Khosla, MD
IRB Approval Number: EH 12-364
Sponsor: Biogen Idec
Contact: For more information, interested participants and clinicians may contact the Nephrology Research Office at 847.570.1761 or email Shonny Fettman at sfettman@northshore.org
Open to Enrollment: Yes

Biodensity
Aims: This is a pilot study to investigate the effects of a resistance training device, Biodensity, on biochemical and functional parameters in End Stage Kidney Disease patients receiving dialysis therapy.
The primary outcome of the study will include baseline and 6 month DXA scan results. The goal will be >3% increase of bone density at either the hip or spine. The secondary outcomes will be changes in biochemical parameters of hemoglobin and dialysis efficiency as measured by kt/v, serum bicarbonate, albumin, parathyroid hormone, C-reactive protein and hemoglobin.
Diagnosis:
Chronic Kidney Disease on Hemodialysis or Peritoneal Dialysis
Principal Investigator:
Stuart Sprague, DO
IRB Approval Number: EH 11-172
Sponsor: Cytochroma
Contact: For more information, interested participants and clinicians may contact the Nephrology Research Office at 847.570.1761 or email Shonny Fettman at sfettman@northshore.org
Open to Enrollment: Yes

SONAR
Aims:
This is a Phase 111, randomized, double-blind, placebo controlled, parallel group trial to study the effect of Atrasentan on renal outcomes in subjects with type 2 diabetes and nephropathy.  The purpose of this study is to see if Atrasentan, an oral drug, can slow the progression of kidney disease.
Diagnosis:
Chronic Kidney Disease, not on dialysis
Principal Investigator: 
Menaka Sarav, MD
IRB Approval Number:
EH 13-259
Sponsor:
  Abbvie
Contact: 
For more information, interested participants and clinicians may contact the Nephrology Research Office at 847.570.1761 or email Shonny Fettman at sfettman@northshore.org
Open to Enrollment:
Yes

START: Strategies Using Darpepoetin alfa to Avoid Transfusions in Chronic Kidney Disease
Aims: This is a two year study comparing two different dosing strategies using Aranesp for the treatment of anemia in patients with Chronic Kidney Disease.
Diagnosis: Anemia; Chronic Kidney Disease
Principal Investigator: Stuart Sprague, DO
IRB Approval Number: EH 12-235
Sponsor: Amgen Inc
Contact: For more information, interested participants and clinicians may contact the Nephrology Research Office at 847.570.1761 or email Shonny Fettman at sfettman@northshore.org
Open to Enrollment: Yes

× Alternate Text